Pfizer And Roche Advance On Their Weight Loss Drug Journeys
Pfizer And Roche Advance On Their Weight Loss Drug Journeys
輝瑞和羅氏在減重藥研究道路上取得進展
After previously discounting a twice-daily version of its weight loss drug due to patients having difficulties tolerating it, Pfizer Inc (NYSE:PFE) moved forward with the once-daily version. On Thursday, Pfizer revealed it will begin studies to evaluate the optimal dose of its weight lose pill during the second half of the year. With the new formulation, Pfizer continues its attempt to catch up to Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NYSE:NVO) who are currently dominating the weight loss drug landscape.
此前Pfizer因患者難以耐受其減肥藥品的兩次日版本而將其打折，現在改爲推出一日版本。週四，Pfizer透露將在年後半段開始對其減肥藥品的最佳劑量進行研究評估。憑藉新配方，Pfizer繼續試圖追趕Eli Lilly和Novo Nordisk目前在減肥藥品市場上占主導地位。
Pfizer Has Struggled To Catch Up To Eli Lilly And Novo Nordisk
Pfizer一直在努力趕超Eli Lilly和Novo Nordisk
What...
E...
登入免費觀看全文
登入/註冊